KRBP vs. FNCH, SRNE, PALI, ALBT, NSTGQ, ELOX, FRTX, TTNP, WINT, and SQZ
Should you be buying Kiromic BioPharma stock or one of its competitors? The main competitors of Kiromic BioPharma include Finch Therapeutics Group (FNCH), Sorrento Therapeutics (SRNE), Palisade Bio (PALI), Avalon GloboCare (ALBT), NanoString Technologies (NSTGQ), Eloxx Pharmaceuticals (ELOX), Fresh Tracks Therapeutics (FRTX), Titan Pharmaceuticals (TTNP), Windtree Therapeutics (WINT), and SQZ Biotechnologies (SQZ). These companies are all part of the "biological products, except diagnostic" industry.
Finch Therapeutics Group (NASDAQ:FNCH) and Kiromic BioPharma (NASDAQ:KRBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk.
21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 10.9% of Kiromic BioPharma shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by insiders. Comparatively, 3.3% of Kiromic BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Finch Therapeutics Group currently has a consensus target price of $210.00, suggesting a potential upside of 7,976.92%. Given Kiromic BioPharma's higher possible upside, equities research analysts plainly believe Finch Therapeutics Group is more favorable than Kiromic BioPharma.
Finch Therapeutics Group's return on equity of 0.00% beat Kiromic BioPharma's return on equity.
In the previous week, Finch Therapeutics Group had 5 more articles in the media than Kiromic BioPharma. MarketBeat recorded 5 mentions for Finch Therapeutics Group and 0 mentions for Kiromic BioPharma. Finch Therapeutics Group's average media sentiment score of 1.38 beat Kiromic BioPharma's score of 0.77 indicating that Kiromic BioPharma is being referred to more favorably in the news media.
Finch Therapeutics Group has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, Kiromic BioPharma has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500.
Finch Therapeutics Group received 9 more outperform votes than Kiromic BioPharma when rated by MarketBeat users. Likewise, 52.63% of users gave Finch Therapeutics Group an outperform vote while only 50.00% of users gave Kiromic BioPharma an outperform vote.
Kiromic BioPharma has lower revenue, but higher earnings than Finch Therapeutics Group. Kiromic BioPharma is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.
Summary
Finch Therapeutics Group beats Kiromic BioPharma on 9 of the 14 factors compared between the two stocks.
Get Kiromic BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Kiromic BioPharma Competitors List
Related Companies and Tools